Vimarsana
Biggest News Aggregation in the World

Page 9 - Johan Dalsgaard News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Johan Dalsgaard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Johan Dalsgaard Today - Breaking & Trending Today

Vicore Pharma Holding AB: Vicore To Host Key Opinion Leader Webinar On C21 For The Treatment of Idiopathic Pulmonary Fibrosis (IPF) - Vimarsana News

Vicore Pharma Holding AB: Vicore To Host Key Opinion Leader Webinar On C21 For The Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Webinar On Thursday, September 30 @ 16:00 CET (10AM ET) With The Medical Doctors And IPF Experts Prof. Toby Maher and Prof. Joanna Porter. GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/

Interim report April - June 2021 - Vimarsana News

Interim report April - June 2021

STOCKHOLM, Aug. 26, 2021 /PRNewswire/ -- Important events during the second quarter In May, Vicore1 announced that it had entered into a collaboration agreement with Alex Therapeutics

Vicore Pharma Holding AB: Interim report April - Vimarsana News

Vicore Pharma Holding AB: Interim report April

STOCKHOLM, Aug. 26, 2021 /PRNewswire/ -- Important events during the second quarter In May, Vicore1 announced that it had entered into a collaboration agreement with Alex Therapeutics

Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19 - Vimarsana News

Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19

/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders...

Interim report January - March 2021: Vicore Pharma Holding AB - Vimarsana News

Interim report January - March 2021: Vicore Pharma Holding AB

318.7 1 There is no dilution effect for potential ordinary shares for periods where earnings have been negative. 2 Alternative performance measure (APM). Defined on page 20 in the interim report. CEO Comments The first quarter of 2021 has been very productive for Vicore continuing to build on the clinical success achieved with C21 in 2020. In the beginning of February, the company raised 336 MSEK (approx. 40 MUSD) in a directed share issue that attracted Swedish and international institutional investors, including existing shareholders. The strengthened financial position allows Vicore to fu...